Year: 2017
Type: article
Abstract: Malignant brain tumors are the most common cause of solid cancer death in children. New targeted therapies are vital to improve treatment outcomes, but must be developed to enable trafficking across the blood brain barrier (BBB). Since activated T cells cross the BBB, cancer immunotherapy can be harnessed to unlock the cytotoxic potential of the immune system. However, standard of care treatments (i.e., chemotherapy and radiation) applied concomitant to pediatric brain tumor immunotherapy may abrogate induction of immunotherapeutic responses. This review will discuss the development of immunotherapies within this paradigm using emerging approaches being investigated in phase I/II trials in children with refractory brain tumors, including checkpoint inhibitors, vaccine immunotherapy, and adoptive cell therapy.
Source: Brain Sciences
Authors: Elias Sayour, Duane Mitchell
Institution: University of Florida
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,654
Awards: G2040153736, Efficacy of Dendritic Cell Vaccines Targeting CMV in Glioblastoma (phase 2 DC vaccine), G3015188539, G3277616900, RNA-NANOPARTICLES TARGETING H3.3 K27M EPITOPES IN DIFFUSE INTRINSIC PONTINE GLIOMA, G4119534169, G5850682332, Enhancing Adoptive Immunotherapy Targeting Pediatric High-Grade Gliomas, ADOPTIVE CELLULAR THERAPY TARGETING RECURRENT PEDIATRIC BRAIN CANCERS DURING HEMATOPOIETIC RECOVERY FROM HIGH-DOSE CHEMOTHERAPY, G9000307279
OpenAlex ID: W2765422255